Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib Long-term Safety and Efficacy in Psoriasis and Psoriatic Arthritis
NCT01519089Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2012
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tofacitinib in plaque psoriasis, psoriatic arthritis (PsA), sponsored by Pfizer. Started Mar 2012; status: completed.
02
Drugs
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT01519089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01519089.